4.5 Article

Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease

Journal

INFLAMMATORY BOWEL DISEASES
Volume 22, Issue 11, Pages 2733-2747

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000000923

Keywords

azathioprine; 6-mercaptopurine; thiopurines; inflammatory bowel disease; therapy

Funding

  1. Vifor Pharma
  2. AbbVie
  3. Falk
  4. MSD
  5. Takeda
  6. UCB Pharma
  7. Tillotts
  8. Receptos
  9. Regeneron
  10. Nestle Health Sciences
  11. Amgen
  12. AstraZeneca
  13. Calypso
  14. Delenex
  15. Ferring
  16. Hospira
  17. Merck-Serono
  18. Pfizer
  19. UCB
  20. Augurix
  21. Boehringer
  22. Fisher
  23. Genentech
  24. Essex/MSD
  25. Novartis
  26. Phadia
  27. Roche
  28. Vital Solutions
  29. Zeller
  30. Ardeypharm
  31. Flamentera
  32. Dr Falk pharma
  33. Atlantic Healthcare

Ask authors/readers for more resources

The relevance of azathioprine and 6-mercaptopurine therapy in inflammatory bowel disease, Crohn's disease, and ulcerative colitis, has been challenged in recent publications. In this article, a panel of experts gives advice, based on the relevant literature, on indications and practical use of azathioprine/6-mercaptopurine, prevention, and management of drug adverse reactions and special situations such as vaccination, pregnancy, and lactation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available